We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Idenix Wins $2.5B Verdict In Gilead Hep C Drug Patent Fight

Law360, Wilmington (December 15, 2016, 5:17 PM EST) -- A federal jury took less than two hours Thursday to award Idenix Pharmaceuticals LLC a $2.54 billion royalty share of Gilead Sciences Inc.'s profits from two blockbuster hepatitis C drugs, after...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.